

Helio Elkis

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/7255716/publications.pdf>

Version: 2024-02-01

92
papers

3,350
citations

201674

27
h-index

155660

55
g-index

105
all docs

105
docs citations

105
times ranked

4096
citing authors

#	ARTICLE	IF	CITATIONS
1	Treatment-Resistant Schizophrenia: Treatment Response and Resistance in Psychosis (TRRIP) Working Group Consensus Guidelines on Diagnosis and Terminology. <i>American Journal of Psychiatry</i> , 2017, 174, 216-229.	7.2	685
2	Meta-analyses of Studies of Ventricular Enlargement and Cortical Sulcal Prominence in Mood Disorders. <i>Archives of General Psychiatry</i> , 1995, 52, 735.	12.3	243
3	Treatment-Resistant Schizophrenia. <i>Psychiatric Clinics of North America</i> , 2007, 30, 511-533.	1.3	198
4	Early Improvement As a Predictor of Later Response to Antipsychotics in Schizophrenia: A Diagnostic Test Review. <i>American Journal of Psychiatry</i> , 2015, 172, 617-629.	7.2	150
5	Reduced Cortical Folding in Schizophrenia: An MRI Morphometric Study. <i>American Journal of Psychiatry</i> , 2003, 160, 1606-1613.	7.2	130
6	Treatment-Resistant Schizophrenia. <i>Psychiatric Clinics of North America</i> , 2016, 39, 239-265.	1.3	123
7	Patterns of regional gray matter loss at different stages of schizophrenia: A multisite, cross-sectional VBM study in first-episode and chronic illness. <i>NeuroImage: Clinical</i> , 2016, 12, 1-15.	2.7	107
8	An International Adult Guideline for Making Clozapine Titration Safer by Using Six Ancestry-Based Personalized Dosing Titrations, CRP, and Clozapine Levels. <i>Pharmacopsychiatry</i> , 2022, 55, 73-86.	3.3	107
9	Pimavanserin, a selective serotonin (5-HT) _{2A} -inverse agonist, enhances the efficacy and safety of risperidone, 2mg/day, but does not enhance efficacy of haloperidol, 2mg/day: Comparison with reference dose risperidone, 6mg/day. <i>Schizophrenia Research</i> , 2012, 141, 144-152.	2.0	87
10	Analysis of a novel functional polymorphism within the promoter region of the serotonin transporter gene (5-HTT) in Brazilian patients affected by bipolar disorder and schizophrenia. , 1998, 81, 225-227.		79
11	Effects of Repetitive Transcranial Magnetic Stimulation on Auditory Hallucinations Refractory to Clozapine. <i>Journal of Clinical Psychiatry</i> , 2007, 68, 1528-1532.	2.2	75
12	Efficacy and Safety of Transcranial Direct Current Stimulation for Treating Negative Symptoms in Schizophrenia. <i>JAMA Psychiatry</i> , 2020, 77, 121.	11.0	72
13	Randomized controlled trial of occupational therapy in patients with treatment-resistant schizophrenia. <i>Revista Brasileira De Psiquiatria</i> , 2003, 25, 26-30.	1.7	70
14	Conjugated estrogens as adjuvant therapy in the treatment of acute schizophrenia: a double-blind study. <i>Schizophrenia Research</i> , 2004, 66, 97-100.	2.0	65
15	Understanding tDCS effects in schizophrenia: a systematic review of clinical data and an integrated computation modeling analysis. <i>Expert Review of Medical Devices</i> , 2014, 11, 383-394.	2.8	61
16	Obsessive-compulsive symptoms among patients with Sydenham chorea. <i>Biological Psychiatry</i> , 2005, 57, 1073-1076.	1.3	60
17	Decreased S100-beta protein in schizophrenia: preliminary evidence. <i>Schizophrenia Research</i> , 2000, 43, 91-95.	2.0	57
18	Obsessive-compulsive symptoms and disorder in patients with schizophrenia treated with clozapine or haloperidol. <i>Comprehensive Psychiatry</i> , 2009, 50, 437-442.	3.1	54

#	ARTICLE	IF	CITATIONS
19	A 6-month randomized controlled trial to test the efficacy of a lifestyle intervention for weight gain management in schizophrenia. <i>BMC Psychiatry</i> , 2013, 13, 60.	2.6	52
20	Efficacy of olanzapine in comparison with clozapine for treatment-resistant schizophrenia: evidence from a systematic review and meta-analyses. <i>CNS Spectrums</i> , 2013, 18, 82-89.	1.2	50
21	A Preliminary Controlled Trial of Cognitive Behavioral Therapy in Clozapine-Resistant Schizophrenia. <i>Journal of Nervous and Mental Disease</i> , 2009, 197, 865-868.	1.0	49
22	A cross-national factor analytic comparison of three models of PANSS symptoms in schizophrenia. <i>Psychiatry Research</i> , 2014, 219, 283-289.	3.3	43
23	Evaluation of the factors interfering with drug treatment compliance among Brazilian patients with schizophrenia. <i>Revista Brasileira De Psiquiatria</i> , 2005, 27, 178-184.	1.7	42
24	Effects of minocycline add-on treatment on brain morphometry and cerebral perfusion in recent-onset schizophrenia. <i>Schizophrenia Research</i> , 2015, 161, 439-445.	2.0	33
25	Clinical aspects of super-refractory schizophrenia: a 6-month cohort observational study. <i>Revista Brasileira De Psiquiatria</i> , 2007, 29, 228-232.	1.7	29
26	Understanding the impact of persistent symptoms in schizophrenia: Cross-sectional findings from the Pattern study. <i>Schizophrenia Research</i> , 2015, 169, 234-240.	2.0	29
27	Rehospitalization rates of patients with schizophrenia discharged on haloperidol, risperidone or clozapine. <i>Revista Brasileira De Psiquiatria</i> , 2007, 29, 207-212.	1.7	28
28	Understanding the course of persistent symptoms in schizophrenia: Longitudinal findings from the pattern study. <i>Psychiatry Research</i> , 2018, 267, 56-62.	3.3	26
29	Components of biological variation in plasma haptoglobin: relationships to plasma fibrinogen and immune variables, including interleukin-6 and its receptor. <i>Clinica Chimica Acta</i> , 1995, 239, 23-35.	1.1	25
30	Time to rehospitalization in patients with schizophrenia discharged on first generation antipsychotics, non-clozapine second generation antipsychotics, or clozapine. <i>Psychiatry Research</i> , 2011, 188, 315-319.	3.3	24
31	Rightward cerebral asymmetry in subtypes of schizophrenia according to Leonhard's classification and to DSM-IV: a structural MRI study. <i>Psychiatry Research - Neuroimaging</i> , 2003, 123, 65-79.	1.8	23
32	Systematic review of dementia prevalence - 1994 to 2000. <i>Dementia E Neuropsychologia</i> , 2007, 1, 230-240.	0.8	23
33	Meta-analysis about efficacy of anti-resorptive drugs in postmenopausal osteoporosis. <i>Journal of Clinical Pharmacy and Therapeutics</i> , 1998, 23, 345-352.	1.5	22
34	Pancreatitis and Cholestatic Hepatitis Induced by Risperidone. <i>Journal of Clinical Psychopharmacology</i> , 2001, 21, 529-530.	1.4	22
35	Increased prefrontal sulcal prominence in relatively young patients with unipolar major depression. <i>Psychiatry Research - Neuroimaging</i> , 1996, 67, 123-134.	1.8	21
36	The psychopathological factors of refractory schizophrenia. <i>Revista Brasileira De Psiquiatria</i> , 2005, 27, 108-112.	1.7	17

#	ARTICLE	IF	CITATIONS
37	Lithium as a treatment of clozapine-induced neutropenia: A case report. <i>Progress in Neuro-Psychopharmacology and Biological Psychiatry</i> , 2008, 32, 2006-2007.	4.8	17
38	Efficacy and Moderators of Cognitive Behavioural Therapy for Psychosis Versus Other Psychological Interventions: An Individual-Participant Data Meta-Analysis. <i>Frontiers in Psychiatry</i> , 2020, 11, 402.	2.6	17
39	A pilot randomized controlled trial of the Occupational Goal Intervention method for the improvement of executive functioning in patients with treatment-resistant schizophrenia. <i>Psychiatry Research</i> , 2016, 245, 148-156.	3.3	15
40	Aripiprazole for Patients with Schizophrenia and Schizoaffective Disorder: An Open-Label, Randomized, Study Versus Haloperidol. <i>CNS Spectrums</i> , 2009, 14, 93-102.	1.2	14
41	Adesão em esquizofrenia. <i>Revista De Psiquiatria Clinica</i> , 2007, 34, 189-192.	0.6	13
42	Efficacy of electroconvulsive therapy augmentation for partial response to clozapine: a pilot randomized ECT "sham controlled trial. <i>Revista De Psiquiatria Clinica</i> , 2017, 44, 45-50.	0.6	13
43	The Brief Negative Symptom Scale: Validation in a multicenter Brazilian study. <i>Comprehensive Psychiatry</i> , 2018, 85, 42-47.	3.1	12
44	Patterns of clozapine and other antipsychotics prescriptions in patients with treatment-resistant schizophrenia in community mental health centers in São Paulo, Brazil. <i>Revista De Psiquiatria Clinica</i> , 2015, 42, 165-170.	0.6	11
45	Can the Positive and Negative Syndrome scale (PANSS) differentiate treatment-resistant from non-treatment-resistant schizophrenia? A factor analytic investigation based on data from the Pattern cohort study. <i>Psychiatry Research</i> , 2019, 276, 210-217.	3.3	11
46	Prevalence and underrecognition of dysthymia among psychiatric outpatients in São Paulo, Brazil. <i>Journal of Affective Disorders</i> , 2002, 69, 193-199.	4.1	10
47	Psychotic symptoms in older people without dementia from a Brazilian community-based sample: A seven years' follow-up. <i>PLoS ONE</i> , 2017, 12, e0178471.	2.5	10
48	Meta-analyses of cavum septum pellucidum in mood disorders in comparison with healthy controls or schizophrenia. <i>European Neuropsychopharmacology</i> , 2018, 28, 1325-1338.	0.7	9
49	Cortical surface abnormalities are different depending on the stage of schizophrenia: A cross-sectional vertexwise mega-analysis of thickness, area and gyrification. <i>Schizophrenia Research</i> , 2021, 236, 104-114.	2.0	9
50	Does lack of improvement in the first two weeks predict treatment resistance in recent-onset psychosis?. <i>Clinics</i> , 2012, 67, 1479-1482.	1.5	9
51	Investigation of possible association between Ser9Gly polymorphism of the D3 dopaminergic receptor gene and response to typical antipsychotics in patients with schizophrenia. <i>Sao Paulo Medical Journal</i> , 2006, 124, 165-167.	0.9	8
52	Long-acting injectable risperidone in partially adherent and nonadherent patients with schizophrenia. <i>Neuropsychiatric Disease and Treatment</i> , 2011, 7, 391.	2.2	8
53	Health-related quality of life in outpatients with schizophrenia: factors that determine changes over time. <i>Social Psychiatry and Psychiatric Epidemiology</i> , 2018, 53, 239-248.	3.1	8
54	<p></p>Correlation of Health-Related Quality of Life in Clinically Stable Outpatients with Schizophrenia</p>. <i>Neuropsychiatric Disease and Treatment</i> , 2019, Volume 15, 3475-3486.	2.2	8

#	ARTICLE	IF	CITATIONS
55	Why we should use long-acting injectable antipsychotics more frequently. Revista Brasileira De Psiquiatria, 2013, 35, 217-218.	1.7	8
56	Structural brain abnormalities in early-onset schizophrenia. Arquivos De Neuro-Psiquiatria, 2006, 64, 741-746.	0.8	7
57	Cognitive outcomes after tDCS in schizophrenia patients with prominent negative symptoms: Results from the placebo-controlled STARTS trial. Schizophrenia Research, 2021, 235, 44-51.	2.0	7
58	Fatores de impacto de publicações psiquiátricas e produtividade científica. Revista Brasileira De Psiquiatria, 1999, 21, 231-236.	1.7	7
59	Provision of a Mobile Uterine Artery Embolization Service to Medically Underserved Areas in Brazil. Journal of Vascular and Interventional Radiology, 2011, 22, 490-496.	0.5	6
60	Switching from oral risperidone to flexibly dosed oral paliperidone extended-release: core symptoms, satisfaction, and quality of life in patients with stable but symptomatic schizophrenia: the RISPALI study. Current Medical Research and Opinion, 2014, 30, 695-709.	1.9	6
61	Estudo-piloto com clozapina em hospital público: resultados de um ano de acompanhamento. Revista Brasileira De Psiquiatria, 2001, 23, 180-187.	1.7	6
62	Cognitive Training for Schizophrenia in Developing Countries: A Pilot Trial in Brazil. Schizophrenia Research and Treatment, 2013, 2013, 1-10.	1.5	5
63	Schizophrenia Treatment with electric Transcranial Stimulation (STARTS): design, rationale and objectives of a randomized, double-blinded, sham-controlled trial. Trends in Psychiatry and Psychotherapy, 2019, 41, 104-111.	0.8	5
64	Current clinical research environment: focus on psychiatry. Revista Brasileira De Psiquiatria, 2007, 29, 283-290.	1.7	5
65	A randomized controlled trial of social skills training for patients with treatment-resistant schizophrenia with predominantly negative symptoms. Psychiatry Research, 2020, 287, 112914.	3.3	4
66	Identifying strategies to improve PANSS based dimensional models in schizophrenia: Accounting for multilevel structure, Bayesian model and clinical staging. Schizophrenia Research, 2021, , .	2.0	4
67	Neuroimagem estrutural e psicopatologia: sintomas positivos e negativos e dilatação ventricular na esquizofrenia. Revista Brasileira De Psiquiatria, 2001, 23, 19-23.	1.7	4
68	Novos antipsicóticos para o tratamento da esquizofrenia. Revista De Psiquiatria Clinica, 0, 34, 193-197.	0.6	3
69	Social dysfunction and skills in schizophrenia: relationship with treatment response and severity of psychopathology. Revista De Psiquiatria Clinica, 2016, 43, 107-111.	0.6	3
70	ECT versus Sham for clozapine-resistant schizophrenia: A secondary analysis of a pilot study based on PANSS-30 individual items. Brain Stimulation, 2020, 13, 1517-1518.	1.6	3
71	Residência médica: competências mínimas e psiquiatria moderna. Revista Brasileira De Psiquiatria, 1999, 21, 137-138.	1.7	3
72	Comments on "weight gain management in patients with schizophrenia during treatment with olanzapine in association with nizatidine". Revista Brasileira De Psiquiatria, 2007, 29, 90-90.	1.7	3

#	ARTICLE	IF	CITATIONS
73	Algumas recomendações para estudos com placebo. Revista Brasileira De Psiquiatria, 2000, 22, 153-154.	1.7	3
74	A six month trial of risperidone versus conventional neuroleptics in young patients with early onset schizophrenia. Schizophrenia Research, 1997, 24, 194.	2.0	2
75	Refractory psychotic symptoms in a patient with homozygous sickle cell disease: A 24-month follow-up. Progress in Neuro-Psychopharmacology and Biological Psychiatry, 2008, 32, 301-303.	4.8	2
76	History and Current Definitions of Treatment-Resistant Schizophrenia. Advances in Biological Psychiatry, 2010, , 1-8.	0.2	2
77	Neuroimaging of Treatment-Resistant Schizophrenia. Advances in Biological Psychiatry, 2010, , 63-73.	0.2	2
78	New Therapeutic Strategies for Resistance to Clozapine and Treatment-Resistant Schizophrenia. Advances in Biological Psychiatry, 2010, , 152-164.	0.2	2
79	Thought and language disorders in very early onset schizophrenia, schizoaffective disorder and bipolar disorder. Revista De Psiquiatria Clinica, 2016, 43, 67-73.	0.6	2
80	Clozapina, esquizofrenia refratária e evidências. Revista Brasileira De Psiquiatria, 2001, 23, 59-60.	1.7	2
81	Brain dysgenesis in late onset schizophrenia (paraphrenia): Comparison with controls and patients with schizophrenia. Schizophrenia Research, 1997, 24, 37.	2.0	1
82	A remissão em esquizofrenia é possível?. Revista De Psiquiatria Clinica, 2007, 34, 160-163.	0.6	1
83	Schizophrenia in Women. , 2020, , 49-58.		1
84	Biology of Schizophrenia: Is Treatment Refractoriness Synonymous with Severity of Illness [A.K.A. Is This a Drug Efficacy Problem or an Expression of Severe Illness?]. , 2014, , 21-30.		1
85	Which are the best evidence-based therapeutic options for clozapine and ECT resistant schizophrenia? A Case-Report. Psychiatry Research, 2021, 305, 114248.	3.3	1
86	Psychosocial Intervention in Schizophrenia. , 2015, , 529-539.		1
87	The stability of the diagnosis of schizophrenia: A pilot study in a brazilian university hospital using the OPCRIT multidagnostic system. Schizophrenia Research, 1997, 24, 6.	2.0	0
88	A questionnaire to assess the burden of the family in chronic schizophrenia: Comparison with families of mood disorders patients. Schizophrenia Research, 1997, 24, 219.	2.0	0
89	Re: Preferential Aggregation of Obsessive-Compulsive Spectrum Disorders in Schizophrenia Patients with OCD. Canadian Journal of Psychiatry, 2008, 53, 73-73.	1.9	0
90	Poster #228 THE USE OF SOCIAL SKILLS INVENTORY IN PATIENTS WITH REFRACTORY AND NON-REFRACTORY SCHIZOPHRENIA. Schizophrenia Research, 2012, 136, S268.	2.0	0

#	ARTICLE	IF	CITATIONS
91	S39. RANDOMIZED AND CONTROLLED TRIAL TO EVALUATE THE EFFICACY OF OCCUPATIONAL THERAPY IN THE REHABILITATION OF EXECUTIVE FUNCTIONS IN PATIENTS WITH TREATMENT-RESISTANT SCHIZOPHRENIA. Schizophrenia Bulletin, 2019, 45, S321-S321.	4.3	0
92	<p>Treatment of Patients with Recently Exacerbated Schizophrenia with Paliperidone Palmitate: A Pilot Study of Efficacy and Tolerability</p>. Neuropsychiatric Disease and Treatment, 2020, Volume 16, 2063-2072.	2.2	0